Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
April 08, 2024 16:01 ET
|
Kineta, Inc.
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts Favorable clinical safety and tolerability profile observed with no dose...
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
March 21, 2024 16:02 ET
|
Kineta, Inc.
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts in the VISTA-101 trial No dose limiting toxicities observed at any dose...
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
March 12, 2024 08:00 ET
|
Kineta, Inc.
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohortsNo dose limiting toxicities observed at any dose levelCleared fifth of six...
Kineta Announces Restructuring and Exploration of Strategic Alternatives
February 29, 2024 08:30 ET
|
Kineta, Inc.
SEATTLE, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
February 22, 2024 08:30 ET
|
Kineta, Inc.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta to Present at Upcoming Investor Conferences
February 14, 2024 08:30 ET
|
Kineta, Inc.
SEATTLE, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
February 07, 2024 08:30 ET
|
Kineta, Inc.
SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
January 17, 2024 08:30 ET
|
Kineta, Inc.
Cleared First Four Monotherapy Doses and Initial Combination Cohort with No Dose Limiting Toxicities at any Dose Level KVA12123 Monotherapy Demonstrated Dose Proportional Induction of...
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
January 04, 2024 08:30 ET
|
Kineta, Inc.
SEATTLE, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer...
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
December 13, 2023 08:30 ET
|
Kineta, Inc.
VISTA Blocking KVA12123 Monoclonal Antibody (mAb) Engineered to Provide Strong Single Agent Anti-Tumor Activity While Minimizing Cytokine Related Adverse Events KVA12123 recognizes a unique VISTA...